Medifast reported a $17.5 million Q3 2026 loss driven by restructuring, while coach productivity rose 54% and management ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else ...

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the personal care industry, including Medifast (NYSE:MED) and its peers.

A new study suggests that women using menopause hormone therapy alongside GLP-1 medications like Wegovy may experience ...

Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base. Management sa ...

Novo released new evidence that its experimental CagriSema injection can improve upon the weight loss with its blockbuster ...

Medifast, Inc. reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales was USD 72.05 million compared to USD 89.41 ...

Could a new drug that makes fat cells self-destruct be the next big GLP-1? CBL-514 targets fat cells, and a new study shows that it was effective in slimming down participants’ waistlines. Early data ...

Recent trials investigating the oral weight loss drug Orforglipron, also known as Foundayo, suggest that the medication shows weight loss benefits across menopausal stages, and may also offer greater ...

Gone are the days of battling obesity with a limited toolbox. With more weight loss supplements and drugs on the market than ever before, deciding which medication is right for you isn't as simple as ...

Medifast (NYSE: MED), the metabolic health and wellness company known for its science-backed comprehensive metabolic health system, Trilivy™, today reported results for the third quarter ended ...